The Ad-p53 Dendritic Cell Therapeutic Vaccine (Ad-p53-DCV) is an investigational immune stimulating therapy designed to activate the immune system to attack tumor cells that express high levels of p53 which occurs in many types of cancer.

The Ad-p53-DCV vaccine is comprised of the cancer patient’s dendritic cells, a type of immune cell, infected in the laboratory with a genetically engineered adenovirus carrying the human p53 gene (Ad-p53).

The Ad-p53-DCV vaccine is then injected into the patient’s skin. The Ad-p53-DCV vaccination treatment is combined with Bristol Myers Squibb nivolumab and ipilimumab immune therapies. Nivolumab and ipilimumab have been approved for the treatment of other forms of cancer.